Liquidia Technologies Inc (LQDA)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Liquidia Technologies Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 27 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 84.10 $ — 93% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
NeutralLiquidia ist ein Biopharma-Unternehmen (Inhalationstherapie YUTREPIA gegen Lungenhochdruck PAH/PH-ILD); in den sechs geprüften Filings gibt es keine KI-Umsatzquelle, keinen belegten operativen KI-Einsatz und kein konkretes KI-Geschäftsrisiko fürs eigene Geschäftsmodell — KI erscheint ausschließlich als generischer IT-Risikoabsatz im Konjunktiv („We … may adopt, use or incorporate artificial intelligence technology … into the information technology systems or software that we use“, also nur ein mögliches künftiges Einführen) samt allgemeinem Verweis auf die KI-Regulierungslandschaft (EU AI Act, SEC-Fokus auf „AI-washing“), nahezu wortgleich in allen vier 10-Qs und beiden 10-Ks; im jüngsten 10-K (05.03.2026) und sämtlichen 10-Qs taucht KI außerhalb dieses Boilerplate-Risikoabschnitts nicht auf.
View the full file — quotes, sources, reviewed filings
Filings Reviewed: 10-Q 2026-05-11 · 10-Q 2025-11-03 · 10-Q 2025-08-12 · 10-Q 2025-05-08 · 10-K 2026-03-05 · 10-K 2025-03-19
Rated on July 8, 2026 · How the Rating Is Built
Growth Score
6 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 114.9% passed
- More than 10% revenue growth is expected for the coming year 63.0% passed
- Share count grows by less than 3% a year 12.2% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 1,005.9% passed
- Gross margin at 40% or higher and without meaningful erosion 91.6% passed
- Goodwill from acquisitions does not grow faster than revenue 1.2% passed
- Net debt below twice EBITDA failed
- Operating cash flow covers the profits of the last three years 107 m failed
- Return on capital at 15% or higher, or up versus two years ago -26.7% failed
- Insiders hold at least 10% or are net buyers 12.7% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 0.9% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 10
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 3.48 | 2.36 – 4.09 | 725 | 535.0% | 5 |
| 12/31/2027 | 5.81 | 4.00 – 7.16 | 1,184 | 66.9% | 5 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 0.70 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.45 | – | 3 | -35.60 | -1,315.40 | -21 | -26 |
| 2025: Q1 | -0.45 | – | 3 | 5.00 | -1,229.70 | -31 | -31 |
| 2025: Q2 | -0.49 | – | 9 | 141.50 | -470.50 | -40 | -41 |
| 2025: Q3 | -0.04 | – | 54 | 1,121.70 | -6.50 | -10 | -11 |
| 2025: Q4 | 0.15 | – | 92 | 3,054.60 | 15.80 | 44 | 42 |
| 2026: Q1 | 0.52 | – | 133 | 4,158.50 | 39.80 | 53 | 50 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 13 | -16 | -16 | -3.13 | -14 | -18 | 8 |
| 2017 | 7 | -28 | -29 | -3.40 | -24 | -34 | 15 |
| 2018 | 3 | -35 | -53 | -7.42 | -32 | 19 | 49 |
| 2019 | 8 | -47 | -48 | -2.57 | -48 | 35 | 69 |
| 2020 | 1 | -59 | -60 | -1.76 | -54 | 71 | 100 |
| 2021 | 13 | -34 | -35 | -0.70 | -34 | 65 | 94 |
| 2022 | 16 | -39 | -41 | -0.67 | -29 | 90 | 129 |
| 2023 | 17 | -73 | -79 | -1.21 | -42 | 47 | 118 |
| 2024 | 14 | -121 | -130 | -1.66 | -93 | 77 | 230 |
| 2025 | 158 | -51 | -69 | -0.80 | -36 | 45 | 328 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Liquidia Corporation, ein biopharmazeutisches Unternehmen, entwickelt, fertigt und vermarktet verschiedene Produkte für seltene kardiopulmonale Erkrankungen in den USA. Zu den führenden Produktkandidaten zählt YUTREPIA, eine inhalative Trockenpulverformulierung von Treprostinil zur Behandlung von pu…
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 216 |
| Headquarters | Morrisville, NC |
| Address | 419 Davis Drive, 27560 Morrisville, United States |
| Phone | 919 328 4400 |
| Website | liquidia.com |
| IPO Date | 26. Jul 2018 |
| ISIN | US53635D2027 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Roger A. Jeffs Ph.D. | CEO & Director | 1962 |
| Michael Kaseta | COO & CFO | 1976 |
| Russell Schundler | General Counsel & Corporate Secretary | 1976 |
| Scott Moomaw | Chief Commercial Officer | 1971 |
| Rajeev Saggar M.D. | Chief Medical Officer | 1975 |
| Dana Boyle | Chief Accounting Officer | 1985 |
| Christian Perez Font | Senior VP, Chief Compliance Officer & Associate General Counsel | – |
| Michael Post | Senior Vice President of Marketing | – |
| Matt Snow | Senior Vice President of Sales | – |
| Sarah Krepp SPHR | Chief Human Resources Officer | 1982 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 27. Jul 2026 | Boyle Dana | Chief Accounting Officer | Sell | 1,600 | 87.53 | 140,048 |
| 27. Jul 2026 | Adair Jason | Chief Business Officer | Sell | 688 | 87.53 | 60,221 |
| 21. Jul 2026 | Bloch Stephen M | Director | Sell | 556 | 80.66 | 44,846 |
| 21. Jul 2026 | Bloch Stephen M | Director | Sell | 74,444 | 79.98 | 5,954,336 |
| 20. Jul 2026 | Bloch Stephen M | Director | Sell | 3,596 | 79.55 | 286,068 |
| 13. Jul 2026 | Krepp Sarah | Chief Human Resource Officer | Sell | 7,306 | 71.52 | 522,525 |
| 13. Jul 2026 | Krepp Sarah | Chief Human Resource Officer | Sell | 558 | 71.39 | 39,836 |
| 13. Jul 2026 | Khindri Sanjeev | Chief Development Officer | Sell | 1,101 | 71.52 | 78,744 |
| 13. Jul 2026 | Khindri Sanjeev | Chief Development Officer | Sell | 84 | 71.39 | 5,997 |
| 13. Jul 2026 | Kaseta Michael | CFO and COO | Sell | 18,977 | 71.52 | 1,357,235 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.